Post Reply
201-220 of 241
Hi all,
I am also holding c no pharm.bot at 405. wondering if i should let go or just get more as the price retreats further if any?
Mr Alex chia, your projected px fo c n o after a year is high. Do yu firmly believe it is possible in the near future for it to goup?I would like to believe it too seeing how is more or less a defensive stock though some may not agree but seeing how the present economic conditions are .... i wonder...
can you gif me your insight?
thank you
Thanks paul1688 and alexchia01 for your very informative posts.
I am monitoring this stock, and may enter tomorrow.
I'm buying C&O Pharm today.
Although, I don't like the price has risen so high yesterday, I still think it's a good Buy.
Beside the good dividends, the companies fundamentals are strong.
On its 3Q to 3Q result, their Revenue, Profit, and Cash Flow has increase around 6%, 60% and 50% respectively.
Their YoY result is also quite good.
My only fear for this counter is any violation of the law, which happen to a few China Companies listed in SGX. Let's cross our fingers and hope this will not happen here.
In the near future, the price may fall after the XD date, but I believe this counter may reach $0.80 within a year or so. A 100% growth potential.
thulasiappan ( Date: 13-May-2010 07:21) Posted:
|
Picked up some interesting views from analysts at Lim&Tan and Phillip per their reports yesterday. Div 2.8 cts to ex-div in 26 Aug, Div 3.5 cts to ex-div on 8 Jul. Did not check if these are taxable. At price of 46 cts, this gives a current div yield of 13.69%. While this sizeable div payout appears to deplete C&O's cash reserves. company management is giving this out on the strong confidence they can easily rebuild their cash reserves with the new sales growth projected (I am paraphrasing here). With a forward looking expected typical annual div of 3 cts after these large payouts, annual yield will still be at 6.5% at today's price not including future special dividends.
Disclaimer : Newly vested and sharing why. Not enticing anyone to blindly buy at this level.
Disclaimer : Newly vested and sharing why. Not enticing anyone to blindly buy at this level.
thulasiappan ( Date: 13-May-2010 07:21) Posted:
|
Is it safe to enter at the current price? Any comments..
sniper ( Date: 12-May-2010 23:19) Posted:
|
super dividend. biz seem sound think pple realise that now. tdy chiong
how come no one here? 4 cents coming in july...better collect now for best price....
Yesterday just start to move, bought at 0.35. Volume up a lot, should be going up further. Think should hold on.
run up so high 2day..sell or wait for dividends or c hw mkt react next week...hmmm, will mkt b as good as tis week..no directions yet
Outlook and Updates:
China drug market is estimated to grow by 18% to RMB 570.6 billion in 2009*
Expansion of Essential Drug System to 60% of state‐run grass roots health institutions by end of 2010#
Two additional C&O Branded products included in the updated National Health Insurance Catalog
-Amoxcillin Granules
-Clarithromycin Dispersible Tablets
Positive outlook supported by strong results
17
* According to SFDA Southern Medicine Economic Institute, based on retail price.
# According to xinhuanet.com, 5 Jan 2010.
New C&O Branded Products to be launched in 3QFY10
Levocarnitine Injection
Cefuroxime Axetil Capsule
18
OctiOcti ( Date: 26-Feb-2010 17:41) Posted:
|
cnt comment much abt e price,cz me buy early. bt if u r holdg tis stock mid/long term, shouldnt be a prob.
OctiOcti ( Date: 26-Feb-2010 17:41) Posted:
|
FA seems ok to me, debt ratio nt high, company gt progress, moreovr wif tis high dividend, but wonder izzit a gd price to buy nw @0.325?
ElondSi ( Date: 26-Feb-2010 17:27) Posted:
|
Tis counter oso give gd dividend , special interim dividend @3.5cent & interim dividend @ 0.5cent = 4cents!!
still queing........ :p
C & O PHARMACEUTICAL TECHNOLOGY (HOLDINGS) LIMITED
Unaudited consolidated income statement of C & O Pharmaceutical Technology (Holdings) Limited (“C&O” or
the “Company”) and its subsidiary companies (the “Group”) for the three and six months ended 31 December 2009
3 months ended 31/12/2009
Profit for the period HK$29.58mlns +17.5% (^_^ )
http://info.sgx.com/webcoranncatth.nsf/VwAttachments/Att_C9FC45A15ED64C10482576C60032F818/$file/2QFY2010.pdf?openelement
Daiwa downgrades C&O Pharmaceutical Technology to Outperform from Buy, citing lack of near-term catalysts. Cuts target price to $0.34 from $0.48, based on P/E of 8.5X earnings for 12 months to 2Q09; "in terms of earnings growth, we have yet to observe a secular change in the trend from previous years, despite the many new ventures and products, and the speedy recovery from its transition in FY07." Says China-based drugmaker unlikely to receive offer to be taken private given current market uncertainty, lower valuations across Asia. But doesn''t rule out possibility; "we note that CMIA Capital Partners, a strategic investor in C&O with a 10.5% stake, is working currently with the management of Midsouth Holdings to privatize the latter. As a result, we believe that such an option would be available to C&O for the right price."
DJ MARKET TALK: Daiwa Raises C&O Pharma To Buy; S$0.48 Target
0053 GMT [Dow Jones] STOCK CALL: Daiwa upgrades C&O Pharmaceutical (E92.SG) to Buy from Outperform; but cuts target price to S$0.48 from S$0.60. Says stock has re-rating potential; "we expect the ongoing privatization at AsiaPharm (A61.SG) to result in a positive re-rating of China companies listed in Singapore, given their potential for relisting at higher P/E ratios on other stock exchanges." Adds, lower target price reflects more conservative outlook, reduction in assumed forward P/E ratio. Shares closed +1.4% at S$0.365 yesterday. (KIG)
C&O Pharmaceutical has been appointed by Japan's Meiji Seika Kaisha as the China distributor for a new-generation cephalosporin antibiotic known as Meiact. The 5-year distributorship beginning from Jan 1 '08, was awarded by Meiji Seika's subsidiary Shantou Meiji Pharmaceuticals. Meiji Seika is a Tokyo-listed food and pharmaceutical company. Prior to the appointment of C&O as the distributor for China, Meiact was marketed in China by Meiji Seika's sales team.
'With C&O's extensive distribution network in China and its strong track record of marketing oral antibiotics, we are confident that Meiact is able to penetrate the market quickly through C&O's comprehensive distribution network.
Launched in Japan by Meiji Seika in '94, Meiact was said to be the first foreign pharmaceutical product to obtain a Category 1 new drug certificate in China. It was launched in China in '01.
For the 12 months ended Mar 31 '07, sales of Meiact in China was about US$4.7 million, said C&O. "This is another testament of our track record and our strengths are recognised by major players in the pharmaceutical industry."
Meiji Seika's total sales for Meiact amounted to US$187 million for the 2007 fiscal year. The product is currently sold in more than 17 countries outside Japan. Meiji Seika is also said to be working with several licensees worldwide, including GlaxoSmithKline and Bayer, for the distribution of Meiact. C&O was listed on Singapore Exchange in 2005.
For the first quarter ended Sep 30 '07, C&O reported a net profit of HK$17.8 million (S$3.30 million) on revenue of HK$121.4 million.
perhaps u will like to wait for a volume surge at $0.61 next week
how about C&O?any comment on next week?
Anyone has any input in this share ? Any good news to be announced ?